D-NAME
D-NAME (NG-Nitro-D-arginine methyl ester) is an orally active enantiomer of L-NAME (HY-18729). D-NAME inhibits Nitric oxide synthase activity in myocardium and aorta (Note: D-NAME was once classified as an inactive substance and used as a negative control in nitric oxide synthase inhibition studies), induces increases in systolic blood pressure and mean arterial blood pressure, reduces mesenteric arterial conductance, elevates the ratio of left ventricular weight to body weight, induces myocardial fibrosis, increases the cross-sectional area of aortic wall, enhances mesenteric vasodilation induced by nitrovasodilators, and releases nitric oxide via its guanidino nitro group. D-NAME has no effect on ovalbumin-induced pulmonary eosinophilia in sensitized mice. D-NAME can be used in hypertension-related research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 141968-19-6
- Formel: C7H15N5O4
- Molecular Weight:233.23
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
D-NAME releases NO, whereas L-Arginine (HY-N0455) or another NOS inhibitor L-NMMA (HY-18732) does not, which is consistent with the presence or absence of nitro groups in their structures and the nitro group's vasodilatory enhancing effect[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
D-NAME (50 mg/kg; i.p.; twice) does not inhibit OVA-induced pulmonary eosinophilia in sensitized male B6D2F1/J mice[2].
D-NAME (222 μmol/kg; i.p.; daily; 4 days) pretreatment potentiates nitrodilator (BDNIC, NTG)-mediated mesenteric vasodilation, increases mean arterial blood pressure, and decreases baseline mesenteric arterial conductance in female Sprague-Dawley rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (male, 15-week-old)[1]
-
Dosage:40 mg/kg/day
-
Administration:p.o.; daily; 4 weeks
-
Result:Increased systolic blood pressure by 27% compared to controls after 4 weeks.
Reached a left ventricular weight-to-body weight ratio (LVW/BW) of 1.44 mg/g, representing a 13% increase compared to controls.
Elevated myocardial fibrosis to 5.25% of heart muscle area, up from 0.94% in controls.
Increased aortic wall cross-sectional area by 25% compared to controls.
Increased DNA concentration in the left ventricle and aorta significantly compared to controls.
Reduced myocardial NO synthase activity by 25% compared to controls, and reduced aortic NO synthase activity by 13% compared to controls.
-
Animal Model:B6D2F1/J (male, 20-25 g, sensitized by i.p. injection of alum-precipitated ovalbumin, boosted 5 days later, then challenged with aerosolized ovalbumin twice in one day)[2]
-
Dosage:50 mg/kg
-
Administration:i.p.; twice (30 minutes before and 4 hours after first antigen challenge)
-
Result:Had no effect on the increased number of eosinophils in the BAL fluid and peribronchial lung tissue induced by OVA challenge in sensitized mice.
-
Animal Model:Sprague-Dawley (female, 301 g)[3]
-
Dosage:222 μmol/kg
-
Administration:i.p.; daily; 4 days
-
Result:Potentiated mesenteric arterial vasodilation in response to BDNIC and NTG, increasing mesenteric conductance relative to control.
Increased mean arterial blood pressure.
Decreased baseline mesenteric arterial conductance.
Caused no change to plasma nitrite concentrations.
Chemical Information
-
CAS. Nr. 141968-19-6
-
Molecular Weight 233.23
-
Formel C7H15N5O4
-
SMILES
N[C@H](CCCNC(N[N+]([O-])=O)=N)C(OC)=O
-
Synonyms
NG-Nitro-D-arginine methyl ester
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)